Regenerative Treatment for Multiple Sclerosis
Multipl Skleroz, bağışıklık sisteminin sinir liflerini çevreleyen koruyucu miyelin kılıfına yanlışlıkla saldırdığı otoimmün bir hastalıktır. Bu, beyin ve vücudun geri kalanı arasında iletişim sorunlarına yol açarak çok çeşitli semptomlara neden olur.
Rejeneratif tıp yaklaşımları, altta yatan bağışıklık disfonksiyonunu ele alarak devrimci bir yaklaşım sunar. Mezenkimal kök hücrelerin (MSC'ler) aşırı aktif bağışıklık tepkisini düzenlemeye yardımcı olan, nöroinflmasyonu azaltan ve potansiyel olarak hasarlı miyelinin onarımını destekleyen güçlü immünomodülatör özellikleri vardır.
MS Types We Treat:
- Relapsing-Remitting MS (RRMS)
- Secondary Progressive MS (SPMS)
- Primary Progressive MS (PPMS)
- Progressive-Relapsing MS
Symptoms We Address
MS can affect many aspects of neurological function. our approach aims to improve these symptoms through regenerative medicine.
How Stem Cells Help With MS
Hastaların Deneyimleri
StemCell Longevita İstanbul'da rejeneratif tıbbı tercih eden hastalardan gerçek sonuçlar
"8 yıllık gerilemeden sonra nihayet tekrar ilerliyormuş gibi hissediyorum. İstanbul'daki ekip bana evdeki nöroloğumun veremediği şeyi verdi — gerçek sonuçlarla desteklenen umut."
"Tedaviden üç ay içinde kızımız bizi isimleriyle çağırmaya başladı. Öğretmenleri, biz tedaviyi bile söylemeden önce fark etti."
How Stem Cells Work for Multiple Sclerosis
MSC therapy for multiple sclerosis targets the autoimmune-driven demyelination, chronic neuroinflammation, and progressive neurodegeneration that characterize MS. Clinical studies suggest that MSCs can modulate the immune attack on myelin, promote remyelination, and provide neuroprotective support to preserve neurological function.
In MS, autoreactive T-cells and B-cells attack the myelin sheath surrounding nerve fibers in the central nervous system. MSCs suppress these autoreactive immune cells and promote regulatory T-cell development, helping to re-establish immune tolerance and reduce the frequency and severity of demyelinating attacks.
MSCs secrete neurotrophic factors including BDNF, NGF, and ciliary neurotrophic factor (CNTF) that support the survival and function of oligodendrocyte precursor cells responsible for myelin production. Clinical research suggests this may promote remyelination of damaged nerve fibers, potentially restoring signal transmission in affected neural pathways.
Chronic neuroinflammation in the brain and spinal cord drives progressive MS disability. MSCs release potent anti-inflammatory mediators that suppress microglial activation and reduce the inflammatory cascade within the central nervous system, creating an environment more favorable for neural repair and recovery.
MSCs provide neuroprotective effects by releasing growth factors that protect surviving neurons and axons from further damage caused by ongoing inflammation and oxidative stress. This neuroprotective action may help slow the progression of disability and preserve existing neurological function in MS patients.
Who Is a Good Candidate?
Candidacy for MS the regenerative approach is determined through comprehensive neurological evaluation, including MRI assessment, EDSS scoring, relapse history, and disease course characterization. Our neurologists evaluate each patient to ensure treatment appropriateness and safety.
Ideal Candidates
- Patients with relapsing-remitting MS (RRMS) who continue to experience relapses or disease progression despite treatment with disease-modifying therapies
- Individuals with secondary progressive MS (SPMS) seeking treatment to slow disability progression and potentially improve existing neurological symptoms
- Patients with primary progressive MS (PPMS) looking for regenerative options, as conventional disease-modifying therapies have limited effectiveness for this MS subtype
- MS patients with moderate disability (EDSS 3.0-6.5) who have preserved some neurological function that may be enhanced and protected through regenerative treatment
- Individuals who are unable to tolerate the side effects of conventional MS medications and seek an alternative immunomodulatory approach
May Not Be Suitable
- Patients in the midst of an acute MS relapse requiring high-dose corticosteroid treatment for stabilization before regenerative therapy can be considered
- Individuals with severe, advanced disability (EDSS above 8.0) with very limited residual neurological function, where the potential for meaningful improvement may be limited
- Patients with active infections or other acute medical conditions that must be resolved before immunomodulatory treatment
- Individuals with other concurrent neurological conditions that may confound MS treatment outcomes and require separate diagnostic evaluation
What Results Can You Expect?
MS regenerative medicine approach results develop gradually as the immunomodulatory and neuroregenerative effects take hold. The following timeline is based on clinical trial data and patient outcomes, though individual responses vary based on MS type, duration, and severity.
Initial Recovery
Treatment is well-tolerated whether administered via IV infusion or intrathecal injection. Patients are monitored for any immediate neurological changes. Most resume normal activities within days.
Early Improvements
Many patients report initial improvements in fatigue levels, bladder function, and sensory symptoms. Reduced frequency of spasticity episodes and improved sleep quality are commonly noted during this period.
Progressive Results
More significant improvements in balance, coordination, walking ability, and cognitive function are typically observed. MRI follow-up may show reduced inflammatory activity and fewer new or enhancing lesions.
Optimal Results
Peak therapeutic effects are generally reached, with measurable improvements in EDSS scores, reduced relapse rates, and enhanced quality of life. Some patients report improvements in vision and fine motor skills.
Long-Term Benefits
Sustained immunomodulatory effects may continue to protect against new relapses and slow disability progression. Some patients benefit from periodic follow-up treatments to maintain therapeutic gains.
Individual results vary. These timelines are based on clinical observations and are not guaranteed outcomes. Your specialist will provide personalized expectations during your consultation.
Your approach Journey
Our comprehensive MS treatment program is led by experienced neurologists and follows international protocols for safety and efficacy.
Step 01: Neurological Assessment
Comprehensive evaluation including MRI review, EDSS scoring, and complete neurological examination.
Step 02: Care Planning
Our specialists develop a personalized treatment protocol based on your MS type and progression.
Step 03: Stem Cell Preparation
Up to 200 million mesenchymal stem cells are prepared for your approach.
Step 04: Treatment Administration
Stem cells are administered via IV infusion and/or intrathecal injection by our neurologist.
Step 05: Follow-Up Protocol
Regular monitoring and follow-up assessments to track improvement and adjust care.
Expert Neurology Team
Our Expert Doctors
Our neurology team has extensive experience treating MS patients with regenerative medicine approach. We use the latest protocols and international standards to ensure the optimal support for our patients.
Frequently Asked Questions
Watch Our Patient Stories & Expert Insights
See real results and hear from our medical team about stem cell therapy treatments, procedures, and patient outcomes.
Tüm Rejeneratif Tıp Uygulamaları
Çeşitli durumlar için kapsamlı rejeneratif tıp uygulamalarımızı keşfedin. Daha fazla bilgi için herhangi bir seçeneğe tıklayın.
İlgili Tedaviler
Parkinson Hastalığı
İlerlemeyi yavaşlatmayı ve dopamin üreten nöronları desteklemeyi amaçlar.
Daha Fazla BilgiOtizm Terapisi
Nörolojik işlevi destekleyebilir ve inflamasyonu azaltabilir.
Daha Fazla BilgiAlzheimer's Disease
Learn about candidacy, delivery, evidence, and follow-up for Alzheimer's Disease.
Daha Fazla Bilgiİlgili Makaleler
İlgili tedaviler ve terapiler hakkında derinlemesine araştırma makalelerimizi ve rehberlerimizi keşfedin.
Serebral Palsi Rejeneratif tıp yaklaşımları: Çocuklar İçin Yeni Umut
Mezenkimal rejeneratif tıp yaklaşımlarınin serebral palsi tedavi manzarasını nasıl dönüştürdüğünü keşfedin - dünya genelinde çocuklar ve aileler için geliştirilmiş motor fonksiyon ve yaşam kalitesi sunuyor.
Makaleyi OkuOtizm Spektrum Bozukluğu için Rejeneratif tıp yaklaşımları
İletişim, sosyal etkileşim ve davranış kalıplarındaki gelişmeler dahil olmak üzere otizm spektrum bozukluğu semptomlarını ele almada rejeneratif tıp yaklaşımlarınin umut verici potansiyelini keşfedin.
Makaleyi Okuİnme Gelişmesi: Kök Hücreler Nörolojik Gelişmeyi Nasıl Destekler
İnme rehabilitasyonunda rejeneratif tıp yaklaşımlarınin potansiyelini, etki mekanizmalarını ve motor ve bilişsel fonksiyonda bildirilen gelişmeleri keşfedin.
Makaleyi OkuDünya Çapında Bu Tedavi Ne Kadar Tutar?
StemCell Longevita'daki bu rejeneratif tıp maliyetlerini diğer ülkelerdeki kliniklerle karşılaştırın.
| Ülke | Tipik Maliyet |
|---|---|
| United States | $25,000 – $50,000+ |
| United Kingdom | £20,000 – £35,000 |
| Germany | €20,000 – €40,000 |
| South Korea | $18,000 – $30,000 |
| StemCell Longevita (Turkey) | €8,950'den Başlayan |
Fiyatlar, göbek kordonu kaynaklı mezenkimal kök hücre (MSC) tedavileri sunan karşılaştırılabilir kök hücre kliniklerinin piyasa araştırmasına dayanmaktadır (2025-2026). Gerçek fiyatlar klinik, hücre sayısı ve duruma göre değişiklik gösterir.
Detailed guides for this condition: